Nemec Jaroslav, Alnajjar Abdulsalam, Albarrak Jasem, A Shaban, Al Otaibi Mariam, Mohanty Asit
Department Of Medical Oncology, Kuwait Cancer Control Center, Kuwait.
Gulf J Oncolog. 2017 Sep;1(25):70-72.
Colorectal cancer (CRC) is the third leading cause of cancer death in the Western world, accounting for approximately 140,000 new cases and more than 51,000 deaths in 2010 in the United States. In Kuwait, CRC is the first most-diagnosed neoplasm among males and overall, the second leading cause of death from cancer. The 5-year survival rate in 2002-2004 was 61% for men and 62% for women. Even after complete resection of the colorectal tumor, distant metastases have been noted to develop in 10%-15% of patients. Of all metastases, those to the liver were found in 20%-30% of cases, and to the lung, in 10%-20%; brain metastases are quite rare. The percentage of CRC patients developing brain metastases during the course of their disease is reported to range from 2% to 12%, but the effect of such metastases on the patient's prognosis is significant. With the advent of new targeted therapies and the resulting improvements in outcome for CRC patients, the management policy for brain metastases has changed. Regardless of the therapy used to address brain metastases, reported median survival ranges from 2.8 months to 6 months. We report a case of brain metastasis in a patient of primary colorectal adenocarcinoma. He was evaluated for convulsion, CT findings showed brain metastasis.
结直肠癌(CRC)是西方世界癌症死亡的第三大主要原因,2010年在美国约有140,000例新发病例和超过51,000人死亡。在科威特,CRC是男性中诊断最多的肿瘤,总体上是癌症死亡的第二大主要原因。2002 - 2004年男性的5年生存率为61%,女性为62%。即使在结直肠肿瘤完全切除后,仍有10% - 15%的患者会发生远处转移。在所有转移中,20% - 30%的病例发生肝转移,10% - 20%发生肺转移;脑转移相当罕见。据报道,CRC患者在病程中发生脑转移的比例为2%至12%,但这种转移对患者预后的影响很大。随着新的靶向治疗的出现以及CRC患者预后的改善,脑转移的管理策略发生了变化。无论用于治疗脑转移的疗法如何,报告的中位生存期为2.8个月至6个月。我们报告一例原发性结直肠腺癌患者发生脑转移的病例。他因抽搐接受评估,CT检查发现脑转移。